For Clinicians
The Epitomee Capsule is designed to provide effective results with favorable safety profile. Adverse events reported by participants were mostly mild and similar between the Epitomee and placebo groups.

Epitomee Medical is a public developer of drug-free, self-administered daily ingestible therapeutic devices for chronic diseases.
epitomeecapsule.comCrawled Nov 19, 2026
The Epitomee Capsule is designed to provide effective results with favorable safety profile. Adverse events reported by participants were mostly mild and similar between the Epitomee and placebo groups.
For individuals who have struggled with portion control, GLP-1 intolerance, or weight rebound, the Epitomee Capsule offers a science-backed solution to help reduce caloric intake while supporting lifestyle changes.
The Epitomee Capsule integrates into daily life to help users manage eating habits and weight goals.
Epitomee is manufactured in state-of-the-art facilities under strict quality controls for safety and reliability.
The page identifies users as potential candidates for the drug-free Epitomee Capsule, which expands in the stomach to promote natural fullness.
Real Responses from Epitomee Capsule Users1
Epitomee develops paradigm-shifting ingestible devices that deploy targeted therapies along the GI tract optimized for oral drug delivery.
Dr. Holly Wyatt and Dr. James Hill discuss weight loss myths in the *Weight Loss And* podcast, focusing on science, lifestyle medicine, and behavior change.
The page describes non-drug alternatives to GLP-1 medications like Zepbound and Wegovy for weight management.
The page highlights challenges with GLP-1 medications like Ozempic and Wegovy, including side effects, cost, and availability.
Epitomee Medical tracks advancements in oral delivery, weight management, and emerging ingestible therapeutic technologies.
The page defines ingestible therapeutic devices as the next generation of oral drug delivery systems.
The page outlines challenges in oral drug delivery and describes Epitomee’s platform addressing them.
Epitomee Capsule led to 7.6% average weight loss in women aged 50 and older, with 29% losing at least 10% bodyweight in 24 weeks
The page directs healthcare providers to a locator tool for authorized distributors of the Epitomee Capsule.
Empowering Weight Management Through Innovation
Epitomee is a drug-free medical device that expands in the stomach to create a sensation of fullness and reduce food intake.
The Epitomee Capsule is a prescription-only, drug-free tool that helps users feel full sooner and eat less.
Epitomee develops paradigm-shifting ingestibledevices that deploy targeted therapies along the GI tract
The Epitomee Capsule is a prescription-only, drug-free support tool for weight management, promoting fullness without stimulants or surgery.
Epitomee Medical Ltd. explains its use of cookies on the website in this cookie policy.
Epitomee Medical Ltd. outlines how it collects and processes user information on its website.
Epitomee Medical presents clinical data from the **RESET study** showing weight loss results for its **Epitomee® Capsule** in women aged 50 and older. The findings will be shared in a poster session at **ObesityWeek 2026**, the Obesity Society’s annual meeting in Washington, DC. The company specializes in weight management medical devices and biologic drug-delivery platforms.
Epitomee Medical presents **RESET study results** showing its **drug-free oral hydrogel capsule** aids weight loss. The findings were unveiled at **ObesityWeek 2024**, a leading obesity research conference hosted by The Obesity Society. The capsule’s efficacy was highlighted as part of Epitomee’s ongoing clinical validation efforts.
Epitomee Medical secures FDA clearance for its ingestible capsule, a prescription weight management device targeting adults with a BMI of 25–40. The device provides a drug-free alternative to support weight loss when combined with diet and exercise. The product aims to address unmet needs in non-pharmacological weight management solutions.
Epitomee Medical raises **$51 million** in an IPO on the Tel Aviv Stock Exchange, achieving a **$200 million pre-money valuation**. Leumi Partners Underwriting and Barak Capital lead the offering, while Nestlé Health Sciences converts a **$7 million** investment, bringing total capital raised to **$58 million**. The company leverages the funds to expand its medical technology platform.
Epitomee Medical secures CE mark approval for its swallowable capsule device, now commercially available in the EU as a medical treatment for weight loss in overweight and obese adults. The company’s device targets metabolic disorders through an ingestible therapeutic platform. Epitomee recently partnered with Nestlé to explore strategic opportunities in the weight management space.